Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2016 Aug 23;5(8):e352. doi: 10.1038/mtna.2016.56

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2016 Official journal of the American Society of Gene & Cell Therapy

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/

PMC Copyright notice

megaTAL efficiently disrupts CCR5 in primary CD4⁺ cells. (a) Timeline representing workflow in primary CD4⁺ cells relative to time of transfection (t = 0), beginning with the addition of anti-CD3/CD28 beads on cryo-preserved CD4⁺ T cells. (b) Surface staining of CCR5 in primary CD4⁺ cells comparing expression in untreated cells or cells transfected with BFP or CCR5 megaTAL mRNA. (c) Representative agarose gels quantifying CCR5 modification by T7 endonuclease assay (surveyor assay; top panel) or by re-cleavage assay (RCA) using a fluorescently labeled forward primer (lower panel). (d) Molecular quantification (n = 3) by T7 (left) or RCA (right) of CCR5 disruption in primary CD4⁺ cells. Values are calculated from fluorescent densitometry (%NHEJ = NHEJ band/sum of NHEJ + undisrupted bands).